Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of tougher times ahead.
Is Johnson & Johnson (JNJ) Among The Stocks ChatGPT Predicts Could Make You Wealthy in 10 Years?
We recently published a list of 15 Stocks ChatGPT Predicts Could Make You Wealthy in 10 Years. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks ChatGPT predicts could make you wealthy in 10 years.
Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
The pharmaceutical company’s latest earnings exceeded Wall Street’s expectations as it braces for one of its top-selling medicines to go off patent in the coming weeks.
J&J Tops Quarterly Profit Estimates on Cancer Drug Sales
Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in demand for the company’s blockbuster psoriasis treatment.
Balanced Expectations Amid Challenges and Opportunities for Johnson & Johnson: Hold Rating Issued
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee
Yahoo Finance11d
Insights Into Johnson & Johnson (JNJ) Q4: Wall Street Projections for Key Metrics
Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2 per share in its forthcoming report, representing a decline of 12.7% year over year. Revenues ...
Wall Street Lunch: AI Project Stargate A Go
Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data centers in the U.S.
Wall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's Been in Over a Decade
What Hartford Funds and Ned Davis Research found was that income stocks more than doubled the average annual return of non-payers -- 9.17% versus 4.27% -- and did so while being less volatile than the benchmark S&P 500. However, high-quality dividend stocks don't grow on trees and require some effort by investors to uncover.
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price target - 13% upside
Morningstar5d
Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Medical-technology and drug company's 2025 sales outlook is below consensus Johnson & Johnson's stock ... from Dow Jones Newswires and The Wall Street Journal. We sell different types of products ...
Stock market today: Asian shares trade mixed after drops for Big Tech leave Wall Street mixed
Asian shares are mixed after gains for oil-and-gas producers helped offset drops for Nvidia and other Big Tech companies on Wall Street.
What did Trump keep — and ditch — from Biden’s Oval Office decor?
Every president gets to decorate the Oval Office to their liking — but sometimes, they keep the decor of their predecessor.